{"id":"sfc","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL5840898","moleculeType":null,"molecularWeight":"427.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The fluticasone propionate component suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, while salmeterol is a long-acting beta-2 agonist that stimulates bronchial smooth muscle relaxation. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained symptom control in obstructive airway diseases.","oneSentence":"SFC is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:31.390Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance treatment"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT05708508","phase":"PHASE3","title":"Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-03-28","conditions":"Kidney Transplant Infection","enrollment":144},{"nctId":"NCT07131189","phase":"PHASE1","title":"A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","startDate":"2024-05-30","conditions":"Locally Advanced/Metastatic Solid Tumors","enrollment":30},{"nctId":"NCT06130722","phase":"PHASE1","title":"First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study","status":"COMPLETED","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","startDate":"2023-12-30","conditions":"Locally Advanced/Metastatic Solid Tumors","enrollment":18},{"nctId":"NCT06582433","phase":"NA","title":"Solution-focused Counseling for Menopausal Symptoms","status":"COMPLETED","sponsor":"Karabuk University","startDate":"2024-09-01","conditions":"Menopause, Menopause Related Conditions, Menopausal Depression","enrollment":44},{"nctId":"NCT07027670","phase":"PHASE2","title":"Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-02-01","conditions":"Cardiac Surgical Procedures, Coronary Artery Bypass, Aortic Valve Disease","enrollment":48},{"nctId":"NCT04967742","phase":"PHASE1","title":"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","status":"COMPLETED","sponsor":"United Biomedical Inc., Asia","startDate":"2021-08-05","conditions":"COVID-19","enrollment":50},{"nctId":"NCT05167253","phase":"PHASE1","title":"A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.","status":"WITHDRAWN","sponsor":"United Biomedical Inc., Asia","startDate":"2022-02-15","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05234346","phase":"NA","title":"ALACOVID Study for Vaccinated Subjects","status":"COMPLETED","sponsor":"Vedic Lifesciences Pvt. Ltd.","startDate":"2022-03-15","conditions":"COVID-19 Respiratory Infection","enrollment":200},{"nctId":"NCT05093595","phase":"NA","title":"the Effect of Trans-nasal Fixation of Endotracheal Tubes for Prone Ventilation","status":"COMPLETED","sponsor":"China Medical University, China","startDate":"2021-10-27","conditions":"Prone Craniotomy, Endotracheal Intubation Fixation","enrollment":30},{"nctId":"NCT04542850","phase":"NA","title":"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-11-15","conditions":"SARS-CoV 2, COVID-19","enrollment":15},{"nctId":"NCT04593225","phase":"NA","title":"Effectiveness of VIRTUAL SFCAMINA STUDY","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2020-04-21","conditions":"Chronic Fatigue Syndrome","enrollment":480},{"nctId":"NCT04854876","phase":"NA","title":"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19","status":"WITHDRAWN","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-08-15","conditions":"SARS-COV 2, Covid19","enrollment":""},{"nctId":"NCT03946059","phase":"NA","title":"Measuring Plasticity in SFC/dACC Following Theta-Burst-Stimulation Using TMS","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-04-30","conditions":"Cognitive Control","enrollment":25},{"nctId":"NCT04020653","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria","status":"WITHDRAWN","sponsor":"Neopharma Japan Co., Ltd.","startDate":"2019-09-06","conditions":"Malaria","enrollment":""},{"nctId":"NCT02997514","phase":"NA","title":"Solution Focused Coaching Strategy Within a Paediatric Multidisciplinary Neuromuscular Clinic","status":"UNKNOWN","sponsor":"Holland Bloorview Kids Rehabilitation Hospital","startDate":"2017-01","conditions":"Neuromuscular Diseases","enrollment":40},{"nctId":"NCT02481141","phase":"NA","title":"Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes","status":"COMPLETED","sponsor":"SBI Pharmaceuticals Co, Ltd.","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":53},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT00461500","phase":"PHASE4","title":"SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Asthma","enrollment":81},{"nctId":"NCT00517634","phase":"PHASE4","title":"Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Asthma","enrollment":23},{"nctId":"NCT00965315","phase":"","title":"A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome","status":"AVAILABLE","sponsor":"National Taiwan University Hospital","startDate":"","conditions":"Diabetes, CVD","enrollment":""},{"nctId":"NCT00934258","phase":"","title":"Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia","status":"AVAILABLE","sponsor":"National Taiwan University Hospital","startDate":"","conditions":"Hyperlipidemia","enrollment":""},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACTIVITIES OF DAILY LIVING IMPAIRED"},{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"BODY TEMPERATURE DECREASED"},{"count":1,"reaction":"CATHETER THROMBOSIS"},{"count":1,"reaction":"CENTRAL OBESITY"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"DISSEMINATED CRYPTOCOCCOSIS"},{"count":1,"reaction":"DISSEMINATED INTRAVASCULAR COAGULATION"}],"_approvalHistory":[],"publicationCount":3100,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SFC","genericName":"SFC","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SFC is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}